GenTrust’s Neurocrine Biosciences NBIX Stock Holding History

GenTrust’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,541	Closed	-$335K	–	268
2026 Q1	$335K	Buy	2,541 +781	+44%	+$104K	0.01%	191
2025 Q4	$250K	Buy	+1,760	New	+$255K	0.01%	239

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GenTrust's NBIX Position: Q2 2026 in Review

GenTrust sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 2,541 shares — an estimated $335K sold.

GenTrust first reported a position in NBIX in Q4 2025 and held it in 2 quarters. The position peaked at $335K in Q1 2026. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

GenTrust reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
GenTrust sold 2,541 Neurocrine Biosciences shares in Q2 2026, an estimated $335K.
GenTrust first reported a position in Neurocrine Biosciences in Q4 2025 and held it in 2 quarters.
GenTrust's Neurocrine Biosciences position peaked at $335K in Q1 2026.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on GenTrust's 13F filing for Q2 2026, filed 6 Aug 2026.